San Francisco, CA – November 8, 2011: Clinical researchers here reported the first results of a pilot study with the anticoagulant Angiomax ® (bivalirudin) as an adjunct to catheter-based ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced Bivalirudin for Injection in the United States. Bivalirudin for Injection, an anticoagulant, is a generic ...

New NSAID Inj Approved for Pain Management Hospira announced the launch of Bivalirudin for Injection, the first generic version of The Medicines Company's Angiomax. Hospira announced the launch of ...

PARSIPPANY, N.J., The Medicines Company today announced an agreement with Sandoz Inc. for the distribution of an authorized generic of ANGIOMAX® (bivalirudin) for injection in the United States.

We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients. Bivalirudin plus a glycoprotein IIb/IIIa inhibitor, as compared with heparin plus a glycoprotein IIb ...

UCB-Bioproducts (UCB-Bio) today announced that it will provide commercial quantities of bivalirudin, the active pharmaceutical ingredient (API) for The Medicine Company's (NASDAQ: MDCO ...

Although a final judgment has not been released by the Court, on Mar 31, 2014, Judge Andrews in the U.S. District Court of Delaware issued his trial opinion regarding the generic Angiomax related ...

Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic ...

CHICAGO (Reuters) - As the commonly used blood thinner heparin is recalled around the world and some doctors worry about shortages, researchers say the anti-clotting drug Angiomax works just as well.

Medicines Co. said the U.S. Patent and Trademark Office granted a one-year extension for the patent on its anticoagulant drug Angiomax, which accounts for almost all the company’s revenue.

But in Medicines Co.'s case, the full-court press isn't for reform, but for something much more specific: a patent extension on its anti-coagulant Angiomax. Medicines applied for a standard patent ...